1)Cowan KE, McKean AJ, Gentry MT, et al:Barriers to use of telepsychiatry:clinicians as gatekeepers. Mayo Clin Proc 94:2510-2523, 2019
2)Kinoshita S, Cortright K, Crawford A, et al:Changes in telepsychiatry regulations during the COVID-19 pandemic:17 countries and regions' approaches to an evolving healthcare landscape. Psycholo Med 1-8, 2020[Epub ahead of Print]
3)Wittson CL, Benschoter R:Two-way television:helping the Medical Center reach out. Am J Psychiatry 129:624-627, 1972
4)World Health Organization:Telemedicine:opportunities and developments in Member States:report on the second global survey on eHealth. 2009 http://www.who.int/goe/publications/goe_telemedicine_2010.pdf(2021年12月1日閲覧)
5)Douglas MD, Xu J, Heggs A, et al:Assessing telemedicine utilization by using Medicaid claims data. Psychiatr Serv 68:173-178, 2017
6)Hashiguchi TCO:Bringing health care to the patient:an overview of the use of telemedicine in OECD countries. 2020 https://www.oecd-ilibrary.org/docserver/8e56ede7-en.pdf?expires=1625387494&id=id&accn(2021年12月1日閲覧)
7)World Health Organization:The impact of COVID-19 on mental, neurological and substance use services:results of a rapid assessment. 2020 https://apps.who.int/iris/rest/bitstreams/1310579/retrieve(2021年12月1日閲覧)
8)Keshvardoost S, Bahaadinbeigy K, Fatehi F:Role of telehealth in the management of COVID-19:lessons learned from previous SARS, MERS, and Ebola outbreaks. Telemed J E Health 26:850-852, 2020
9)Hassan A, Mari Z, Gatto EM, et al:Global survey on telemedicine utilization for movement disorders during the COVID-19 pandemic. Mov Disord 35:1701-1711, 2020
10)Fagiolini A, Cuomo A, Frank E:COVID-19 diary from a psychiatry department in Italy. J Clin Psychiatry 81:20com13357, 2020
11)Yellowlees P, Nakagawa K, Pakyurek M, et al:Rapid conversion of an outpatient psychiatric clinic to a 100% virtual telepsychiatry clinic in response to COVID-19. Psychiatr Serv 71:749-752, 2020
12)Dash S, Aarthy R, Mohan V:Telemedicine during COVID-19 in India—a new policy and its challenges. J Public Health Policy 42:501-509, 2021
13)Mehrotra A, Bhatia RS, Snoswell CL:Paying for telemedicine after the pandemic. JAMA 325:431-432, 2021
14)Kalhori SRN, Bahaadinbeigy K, Deldar K, et al:Digital health solutions to control the COVID-19 pandemic in countries with high disease prevalence:literature review. J Med Internet Res 23:e19473, 2021
15)Sathian B, Asim M, Banerjee I, et al:Impact of COVID-19 on clinical trials and clinical research:a systematic review. Nepal J Epidemiol 10:878-887, 2020
16)Asaad M, Habibullah NK, Butler CE:The impact of COVID-19 on clinical trials. Ann Surg 272:e222-e223, 2020
17)European Medicines Agency:Guidance on the management of clinical trials during the COVID-19(coronavirus)pandemic version 4.2021 https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf(2021年12月1日閲覧)
18)Food and Drug Administration:Conduct of clinical trials of medical products during the COVID-19 public health emergency. 2020 https://www.fda.gov/media/136238/download(2021年12月1日閲覧)
19)ヘルスケア・イノベーション協議会バーチャル治験意見交換会:「患者中心の治験」の実現—日常生活からの医薬品・医療機器・再生医療等製品開発.2021 http://platinum.mri.co.jp/sites/default/files/page/vct-teigen.pdf(2021年12月1日閲覧)
20)日本製薬工業協会:医療機関への来院に依存しない臨床試験手法の導入及び活用に向けた検討.2020 https://www.jpma.or.jp/information/evaluation/results/allotment/lofurc0000005jr6-att/tf3-cdt_00.pdf(2021年12月1日閲覧)
21)医薬品医療機器総合機構:新型コロナウイルス感染症の影響下での医薬品,医療機器及び再生医療等製品の治験実施に係るQ&Aについて.2020 https://www.pmda.go.jp/files/000235164.pdf(2021年12月1日閲覧)
22)Guinart D, Marcy P, Hauser M, et al:Patient attitudes toward telepsychiatry during the COVID-19 pandemic:a nationwide, multisite survey. JMIR Ment Health 7:e24761, 2020
23)Basit SA, Mathews N, Kunik ME:Telemedicine interventions for medication adherence in mental illness:a systematic review. Gen Hosp Psychiatry 62:28-36, 2020
24)Krzystanek M, Krysta K, Skałacka K:Treatment compliance in the long-term paranoid schizophrenia telemedicine study. J Technol Behav Sci 2:84-87, 2017
25)Wong MYZ, Gunasekeran DV, Nusinovici S, et al:Telehealth demand trends during the COVID-19 pandemic in the top 50 most affected countries:infodemiological evaluation. JMIR Public Health Surveill 7:e24445, 2021
26)Vogels EA:Digital divide persists even as lower-income Americans make gains in tech adoption. 2021 https://www.pewresearch.org/fact-tank/2021/06/22/digital-divide-persists-even-as-americans-with-lower-incomes-make-gains-in-tech-adoption/(2021年12月1日閲覧)
27)Choi NG, Dinitto DM:The digital divide among low-income homebound older adults:internet use patterns, eHealth literacy, and attitudes toward computer/Internet use. J Med Internet Res 15:e93, 2013
28)Wong KTG, Liu D, Balzan R, et al:Smartphone and internet access and utilization by people with schizophrenia in south Australia:quantitative survey study. JMIR Ment Health 7:e11551, 2020
29)Naslund JA, Aschbrenner KA, Araya R, et al:Digital technology for treating and preventing mental disorders in low-income and middle-income countries:a narrative review of the literature. Lancet Psychiatry 4:486-500, 2017
30)Crawford A, Serhal E:Digital health equity and COVID-19:the innovation curve cannot reinforce the social gradient of health. J Med Internet Res 22:e19361, 2020
31)Kim AY, Choi WS:Considerations on the implementation of the telemedicine system encountered with stakeholders' resistance in COVID-19 Pandemic. Telemed J E Health 27:475-480, 2021
32)Choi WS, Park J, Choi JYB, et al:Stakeholders' resistance to telemedicine with focus on physicians:utilizing the Delphi technique. J Telemed Telecare 25:378-385, 2019
33)Kinoshita S, Kishimoto T:Current status and challenges of the dissemination of telemedicine in Japan after the start of the COVID-19 pandemic. Telemed J E Health:2021(in press)
34)日刊薬業:国内のDCT普及遅延でドラッグラグ発生も—東京センタークリニック・長嶋氏,IQVIAセミナーで.2021 https://nk.jiho.jp/article/165334(2021年12月1日閲覧)
35)Kishimoto T, Kinoshita S, Bun S, et al:Japanese project for telepsychiatry evaluation during COVID-19:treatment comparison trial(J-PROTECT):rationale, design, and methodology. Contemp Clin Trials 111:106596, 2021[Epub ahead of Print]
36)慶應義塾大学:慶應義塾大学とMICINがオンライン診療を用いた重症度評価に関する研究を開始—神経発達症におけるビデオ通話を活用したアクセシビリティ向上と中央評価実現へ.2020 https://www.keio.ac.jp/ja/press-releases/files/2020/8/18/200818-1.pdf(2021年12月1日閲覧)